Giredestrant Combination Extends Progression-Free Survival in Advanced ER-Positive Breast Cancer

Results from the Phase III evERA Breast Cancer study, published in The New England Journal of Medicine, show that investigational giredestrant combined with everolimus significantly improved progression-free survival. This was observed in individuals with estrogen receptor (ER)-positive locally advanced or metastatic breast cancer. The oral selective estrogen receptor degrader (SERD) combination reduced disease progression or death risk by 44% overall, and 62% in the ESR1-mutated population, offering a promising new treatment.